Ken Griffin Ironwood Pharmaceuticals Inc Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$5.58 - $8.61 $831,420 - $1.28 Million	-149,000 Reduced 90.14%	16,300 $106,000
Q1 2024 May 15, 2024	BUY	$8.32 - $15.45 $1.32 Million - $2.46 Million	159,200 Added 2609.84%	165,300 $1.44 Million
Q4 2023 Feb 14, 2024	SELL	$8.79 - $11.51 $10,547 - $13,812	-1,200 Reduced 16.44%	6,100 $69,000
Q3 2023 Nov 14, 2023	BUY	$8.25 - $11.35 $35,475 - $48,805	4,300 Added 143.33%	7,300 $70,000
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $3,030 - $3,480	300 Added 11.11%	3,000 $31,000
Q1 2023 May 15, 2023	BUY	$10.37 - $12.56 $6,221 - $7,536	600 Added 28.57%	2,700 $28,000
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $20,790 - $26,103	2,100 New	2,100 $26,000

244

168M

11.2M

28.5K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $760M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.